Cost-effectiveness of pravastatin for primary prevention of coronary artery disease in Japan

The cost-effectiveness of pravastatin therapy differs substantially according to the level of cardiac risk. At present, pravastatin therapy is not cost-effective for persons at low cardiac risk.